AGM Information • Mar 22, 2024
AGM Information
Open in ViewerOpens in native device viewer

Milan, 22nd March 2024 – Please be informed that the following reports approved by the Board of Directors of Recordati S.p.A. on 19th March 2024:
are available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.it, the first report in the Governance - Remuneration section; and the other reports in the Investors - Shareholder Information section) and on the '' storage mechanism ().
Recordati (Reuters RECI.MI, Bloomberg REC IM) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care, consumer healthcare, and rare diseases. We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege. We want to support people in unlocking the full potential of their lives. We have fully integrated operations across research & development, chemical and finished product manufacturing through to commercialisation and licensing. Established in 1926, Recordati operates in approximately 150 countries across EMEA, Americas and APAC regions. At the end of 2023, Recordati employed over 4,450 people and consolidated revenue of € 2,082.3 million. For more information, please visit www.recordati.com
Investor Relations Eugenia Litz +44 7824 394 750 [email protected] Investor Relations Lucia Abbatantuoni +39 337 1025645 [email protected] Media Relations Brunswick: Barbara Scalchi / Andrea Mormandi +39 02 9288 6200 [email protected]
Registered office VIA M. CIVITALI, 1 20148 MILAN, ITALY TEL. +39 0248787.1 FAX +39 0240073747 SHARE CAPITAL € 26,140,644.50 fully paid up BUSINESS REGISTER OF MILAN, MONZA, BRIANZA and LODI 00748210150 TAX CODE/VAT NO. 00748210150 MILAN ECONOMIC AND ADMINISTRATIVE INDEX (REA) 401832
Company subject to management and coordination by Rossini Luxembourg S.àr.l
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.